Neoadjuvant FOLFOXIRI chemotherapy with or without camrelizumab in the treatment of locally advanced rectal cancer: a retrospective cohort study.

NPJ Precis Oncol · 2026 · PMC13230897 · PMID 41935188

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Overall, the camrelizumab group showed higher pCR and overall CR rates, more frequent downstaging, and a numerically higher anal preservation rate, although the differences in anal preservation and pCR rates did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.